Colon cancer tumor profile panels assess 40 to 400 genetic mutations in tumors. KRAS NRAS, BRAF, MSI markers. Genetic analysis helps to predict chemotherapy toxicity. Gene profiling to select chemotherapy. DNA analysis to find people at risk for colorectal cancers.
Transcript of video
Colon cancer precision treatment is based on genetic profile of tumor. It also includes genetic profile of patient. They interact in clinical colon cancer disease. Leading German-American colorectal cancer oncologist discusses colon cancer. Importance of both genetic profile of colon cancer tumor AND genetic makeup of the patient. Doctors can monitor how colon cancer tumor genetic profile changes under treatment. Tumor molecular escape under chemotherapy for colorectal cancer treatment. Molecular makeup of the colon cancer patient is important for cancer initiation and progression. Genetic profile of patient can identify risk for colorectal cancer development before colon cancer appears. Metastatic spread of colon cancer in younger patients is different from older colon cancer patients. Colorectal cancer targeted chemotherapy options. Advanced stage 4 colon cancer treatment by targeted chemotherapy. Medical second opinion confirms colorectal cancer diagnosis at genetic level. Medical second opinion also confirms colon cancer cure is possible in metastatic colon cancer. Best precision medicine treatment for advanced stage 4 colon cancer with metastatic lesions. Medical second opinion helps to select a personalized medicine targeted treatment for stage 4 colorectal cancer. Get medical second opinion on advanced colorectal cancer. Be confident that your precision medicine treatment is the best. Best colorectal cancer treatment based on tumor markers and gene profiling. Video interview with leading expert in metastatic colorectal cancer treatment from California. Colon cancer personalized medicine. Precision treatment of colon cancer. Dr. Anton Titov, MD. We already discussed colon cancer tumor biomarkers. We also talked about personalized medicine for diagnostics and precision medicine for treatment of colon cancer and rectal cancer patients. What are the most important genetic changes in the tumor in the colon cancer and rectal cancer? What genetic tumor changes might be the targets of the future therapies for colon cancer? Dr. Heinz-Josef Lenz, MD (Colorectal Cancer Expert, California). I think it’s very important. Absolutely critical molecular markers should be tested in each patient diagnosed with metastatic colon cancer. These are KRAS, NRAS, BRAF, and Microsatellite Instability (MSI). I think these colon cancer tumor markers are the minimum to obtain in every colon cancer patient. Now usually in the U.S., most of my colleagues use a panel of 40 to 400 genes for colon cancer molecular tumor profiling. These genes cover many additional genetic alterations in colon cancer tumors. Some of the mutations have potential for prediction of best metastatic colon cancer treatment medication. Some genetic mutations have prognostic implications for patients with colon cancer. Dr. Heinz-Josef Lenz, MD (Colorectal Cancer Expert, California). I think in the future we will all use a large colon cancer genetic mutation panel. It will help us to better understand the tumor behavior and prognosis for colon cancer patient. I think a lot has changed from a year ago or two years ago. Previously we were able only to detect colon cancer tumor mutations at the time of diagnosis. Now we are able to monitor how colon cancer tumor genetic profile changes during treatment. We can see how the colon cancer tumor tries to escape the effectiveness of chemotherapy. this helps to treat colorectal cancer better. These mechanisms of tumor molecular escape may be critical to understand cancer. What would be the next best treatment option for colon cancer patient? There are many different new medications available. We can choose the best colon cancer treatment based on continuous molecular profiling of tumor. I think that is absolutely critical. Dr. Heinz-Josef Lenz, MD (Colorectal Cancer Expert, California). Now we talked a lot about the molecular makeup of the colon cancer tumor. But we have not talked about the molecular makeup of the colon cancer patient. I think we need to identify patients who may be at risk for certain cancers. Because some patients have right-sided colon cancer before the age of 50. They have poorly differentiated carcinomas with mucinous features. These younger colon cancer patients are at higher risk to have a genetic predisposition for colon cancer.This is important for identifying families at risk for colorectal cancer. We can direct them into genetic counseling and screening. But genetic testing of the patient at risk for colon cancer development is crucial. Patients already have colon cancer. Cancer diagnosis has predictive and prognostic implications for colon cancer development in the entire family. The metastatic spread of colon cancer in younger patients is different. The access to potential immunotherapy for colon cancer is showing incredible promise. Identifying these patients with colon cancer early is important. It will have an impact on the individual patients. It will help to predict cancer risk in their families. Because we know that identifying patients with the genetic predisposition to colon cancer is very important. Cancer screening helps. Sometimes patients at risk of colon cancer are involved in screening. Then no one dies of colon cancer anymore. I think we will have in the future a molecular profiling of the colon cancer tumor. We will also have a molecular profiling of the patient. This is particularly true for genetic predispositions to colon cancer. Dr. Anton Titov, MD. This is very important to know. Because prevention of colon cancer is the best treatment. That’s correct. Colon cancer precision treatment depends on both tumor and patient’s genetic profile. Molecular profiling of patient is important. Stage 4 colon cancer chemotherapy.